MSA Safety Incorporated

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for multiple system atrophy (MSA), a rare neurodegenerative disease with no approved disease-modifying therapies.  MSA is a rapidly progressive disorder that affects autonomic functions such as blood pressure and bladder control, as well as motor control, leading to severe disability and shortened life expectancy.

Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain. Despite aggregate weakness, 29 Dividend Kings appear both undervalued and offer a long-term expected return of at least 10%. Recent dividend increases and higher projected earnings growth have modestly improved the Kings' average dividend growth rate to 4.49%.

Integrated Technology Helps to Find Firefighters, New Design Features Reduce Weight, Enhance Comfort PITTSBURGH, Sept. 23, 2026 /PRNewswire/ -- At fire scenes, firefighter safety means more than air supply, it can also mean connectivity, accountability and the ability to quickly locate firefighters in distress.

MSA Safety Incorporporated (NYSE: MSA - Get Free Report) and ESAB (NYSE: ESAB - Get Free Report) are both mid-cap industrials companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk. Earnings and Valuation This table compares MSA